Given that four analogs displayed relatively selective profiles from the PDSP the data was not collected in full for analog 38, however the molecule was assessed separately for activity against the MOR, KOR, and DOR as these are relevant to the pain signaling process. The data confirms that analog 38 did not display any significant off-target modulation of the ORs at 10 µM (Table ) similar to 1, 16, 20, and 39. The data as a whole suggests that this compound series is not inhibiting AC1 activity through agonism of a known Gi/o-linked GPCR.